A phase I pharmacokinetic and pharmacodynamic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group Study
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2013
At a glance
- Drugs Temsirolimus (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 01 Mar 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Nov 2006 New trial record.